Skip to main content
S&P 5007,670.12+1.03%DOW52,648.30+1.12%NASDAQ26,375.87+1.13%BTC$77,135.00+0.09%ETH$2,547.11+3.61%GOLD$4,400.80-0.15%OIL$99.70-2.71%
Smart Investors Daily
AH

OTC · AHKSY

Asahi Kasei Corporation

Basic Materials · Chemicals

$20.37

Up+$0.43 (+2.13%)

Updated Sep 11, 2026, 4:38 PM

SID Score

6.7/10

Composite research score

Smart Money

46/100

Neutral

Market cap
15.97B
P/E ratio
15.94
Dividend yield
2.69%
52-week range
— – —
Volume
4.81K
Avg. volume
19.1K

Price performance

AHKSY price history

1M range · 0 trading sessions · Daily adjusted prices

AHKSY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AHKSY news

The latest Smart Investors Daily articles mentioning AHKSY.

Stock researchCompany · Overview

AHKSY research

Overview

Company profile and research snapshot.

Company profile

ASAHI KAISEI CRP UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$19.19
Implied upside
—
Analysts
17
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients

Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, today announced that the first participant has been dosed in its Phase 2 clinical trial [NCT07290777] of pegrizeprument, a novel investigational maintenance immunosuppressive agent being studied for prevention of organ rejection in kidney transplant recipients.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By